Docoh
Loading...

ZYME Zymeworks

Press releases

From Benzinga Pro
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
19 Nov 21
Press Releases
Full presentation available December 8 at 5:00 pm Central Time (CT) Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
9 Nov 21
Press Releases
HERIZON-GEA-01 study is now open and enrolling patients to evaluate zanidatamab and chemotherapy with or without tislelizumab, versus standard of care Phase 2 data demonstrate potential benefit of zanidatamab in
Zymeworks to Present at Upcoming Investor Conferences
8 Nov 21
Press Releases
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences. Stifel 2021
Zymeworks Reports 2021 Third Quarter Financial Results
3 Nov 21
Press Releases
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2021. "This year, we
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
26 Oct 21
Press Releases
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to provide details related to
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
5 Oct 21
Press Releases
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
16 Sep 21
Press Releases
Confirmed objective response rate (cORR) of 75% overall and 93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP) Median duration of response (mDOR) of 16.4 months and median progression free survival (mPFS)
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
12 Sep 21
Press Releases
Abstract data demonstrate encouraging antitumor activity in first-line GEA Full ESMO presentation available September 16 at 8:30 am CEST, 2:30 am ET Conference call and webcast with principal investigator, Dr.